SG11201900745VA - Substituted thiazolo-pyridine compounds as malt1 inhibitors - Google Patents

Substituted thiazolo-pyridine compounds as malt1 inhibitors

Info

Publication number
SG11201900745VA
SG11201900745VA SG11201900745VA SG11201900745VA SG11201900745VA SG 11201900745V A SG11201900745V A SG 11201900745VA SG 11201900745V A SG11201900745V A SG 11201900745VA SG 11201900745V A SG11201900745V A SG 11201900745VA SG 11201900745V A SG11201900745V A SG 11201900745VA
Authority
SG
Singapore
Prior art keywords
nande
pune
village
taluka
mulshi
Prior art date
Application number
SG11201900745VA
Other languages
English (en)
Inventor
Gagan Kukreja
Nageswara Irlapati
Arun Jagdale
Gokul Deshmukh
Vinod Vyavahare
Kiran Kulkarni
Neelima Sinha
Venkata Palle
Rajender Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of SG11201900745VA publication Critical patent/SG11201900745VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
SG11201900745VA 2016-07-29 2017-07-28 Substituted thiazolo-pyridine compounds as malt1 inhibitors SG11201900745VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621026107 2016-07-29
PCT/IB2017/054612 WO2018020474A1 (en) 2016-07-29 2017-07-28 Substituted thiazolo-pyridine compounds as malt1 inhibitors

Publications (1)

Publication Number Publication Date
SG11201900745VA true SG11201900745VA (en) 2019-02-27

Family

ID=59745317

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900745VA SG11201900745VA (en) 2016-07-29 2017-07-28 Substituted thiazolo-pyridine compounds as malt1 inhibitors

Country Status (15)

Country Link
US (1) US20190275012A9 (es)
JP (1) JP2019522035A (es)
KR (1) KR20190033607A (es)
CN (1) CN110312724A (es)
AU (1) AU2017302182B2 (es)
CA (1) CA3032334A1 (es)
CL (1) CL2019000221A1 (es)
DO (1) DOP2019000020A (es)
IL (1) IL289474A (es)
MX (1) MX2019001132A (es)
PE (1) PE20190656A1 (es)
PH (1) PH12019500214A1 (es)
RU (1) RU2019104890A (es)
SG (1) SG11201900745VA (es)
WO (1) WO2018020474A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3592731A4 (en) * 2017-03-08 2020-10-07 Cornell University MALT1 INHIBITORS AND THEIR USES
EP3710441A1 (en) * 2017-11-17 2020-09-23 Hepagene Therapeutics, Inc. Urea derivatives as inhibitors of ask1
US10888550B2 (en) 2018-06-18 2021-01-12 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors
CN112585128B (zh) 2018-06-18 2023-02-21 詹森药业有限公司 作为malt1抑制剂的吡唑衍生物
CN109265453A (zh) * 2018-10-23 2019-01-25 华侨大学 一种用作caspase-3激活剂的缩氨基脲类衍生物及其应用
EP3888652A4 (en) 2018-11-28 2022-10-19 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
KR20210151880A (ko) 2019-04-11 2021-12-14 얀센 파마슈티카 엔.브이. Malt1 억제제로서의 피리딘 고리 함유 유도체
TW202115077A (zh) * 2019-07-01 2021-04-16 大陸商上海齊魯銳格醫藥研發有限公司 Ｍａｌｔ１抑制劑及其用途
WO2021063735A1 (en) * 2019-10-02 2021-04-08 Basf Se New bicyclic pyridine derivatives
JP2023509886A (ja) * 2019-12-27 2023-03-10 シュレーディンガー， インコーポレイテッド 環式化合物およびその使用方法
JPWO2021241611A1 (es) 2020-05-27 2021-12-02
US20230235077A1 (en) 2020-06-24 2023-07-27 The General Hospital Corporation Materials and methods of treating cancer
WO2022101676A1 (en) * 2020-11-12 2022-05-19 Monopteros Therapeutics,Inc. Materials and methods of treating cancer
WO2023148501A1 (en) 2022-02-03 2023-08-10 C4X Discovery Limited Heterocyclic derivatives as malt1 inhibitors
WO2023192506A1 (en) * 2022-03-31 2023-10-05 Rarified Biosciences, Inc. Malt1 modulators and uses thereof
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
HUP0203160A3 (en) * 1999-11-05 2006-02-28 Warner Lambert Co Prevention of plaque rupture by acat inhibitors
WO2003090746A1 (en) * 2002-04-23 2003-11-06 Chugai Seiyaku Kabushiki Kaisha 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
US9051595B2 (en) 2007-06-01 2015-06-09 University Of Lausanne Malt1 specific cleavage in assay and screening method
ATE553769T1 (de) 2007-11-21 2012-05-15 Vib Vzw Inhibitoren der malt1-proteolytischen aktivität und ihre verwendung
CA2842976A1 (en) * 2011-07-26 2013-01-31 Grunenthal Gmbh Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands
ES2716276T3 (es) * 2011-08-02 2019-06-11 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Inhibición selectiva de proteasa MALT1 mediante derivados de fenotiazina
WO2013053765A1 (en) 2011-10-11 2013-04-18 Proyecto De Biomedicina Cima, S.L. A non-human animal model of mucosa-associated lymphoid tissue (malt) lymphoma
SG11201503642YA (en) 2012-11-09 2015-06-29 Univ Cornell Small molecule inhibitors of malt1
WO2014086478A1 (en) 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of malt1 protease
EP3013818B1 (en) 2013-06-26 2021-12-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (s)-enantiomer of mepazine as paracaspase (malt1) inhibitor for treating cancer
WO2015110406A1 (en) 2014-01-21 2015-07-30 Helmholtz Zentrum München Means and methods for detecting activated malt1
LT3149001T (lt) 2014-05-28 2019-08-12 Novartis Ag Naujieji pirazolo pirimidino dariniai ir jų panaudojimas kaip malt1 inhibitorių
DE102015210224A1 (de) 2015-06-02 2016-12-08 Universitätsklinikum Hamburg-Eppendorf Neuer wirkstoff zur behandlung von krebs
US10711036B2 (en) 2015-08-28 2020-07-14 Cornell University MALT1 inhibitors and uses thereof
WO2017057695A1 (ja) 2015-09-30 2017-04-06 東レ株式会社 ジフェニルピラゾール誘導体及びその医薬用途
BR112018009511A2 (pt) 2015-11-13 2018-11-06 Novartis Ag derivados de pirazolo pirimidina
EP3592731A4 (en) * 2017-03-08 2020-10-07 Cornell University MALT1 INHIBITORS AND THEIR USES

Also Published As

Publication number Publication date
RU2019104890A3 (es) 2020-08-31
IL289474A (en) 2022-02-01
MX2019001132A (es) 2019-12-16
CN110312724A (zh) 2019-10-08
CA3032334A1 (en) 2018-02-01
WO2018020474A1 (en) 2018-02-01
PH12019500214A1 (en) 2019-10-28
US20190275012A9 (en) 2019-09-12
JP2019522035A (ja) 2019-08-08
AU2017302182A1 (en) 2019-03-07
RU2019104890A (ru) 2020-08-31
CL2019000221A1 (es) 2019-06-07
DOP2019000020A (es) 2019-04-30
KR20190033607A (ko) 2019-03-29
PE20190656A1 (es) 2019-05-08
US20190160045A1 (en) 2019-05-30
AU2017302182B2 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
SG11201900745VA (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201808242UA (en) Methods for inhibiting angiogenesis in a subject in need thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201809301YA (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201901548SA (en) Anti-tim-3 antibodies and use thereof
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201808990QA (en) Compositions for topical application of compounds
SG11201809299QA (en) Formulations of an lsd1 inhibitor
SG11201909022PA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201810371XA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201908179UA (en) Aryl cyclopropyl-amino-isoquinolinyl amide compounds
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201809751XA (en) Egfr inhibitor compounds
SG11201901597UA (en) Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
SG11201903786UA (en) Farnesyltransferase inhibitors for use in methods of treating cancer